Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 6/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4512981 | 0.87 | NR3C1 (0.61) | NR3C1L3MBTL1HTT | |
| SCHEMBL4517755 | 0.87 | NR3C1 (0.61) | NR3C1L3MBTL1HTT | |
| SCHEMBL4517020 | 0.82 | HTT (0.44) | NR3C1L3MBTL1ALDH1A1HPGDHTT | |
| SCHEMBL4511719 | 0.82 | PARP1 (0.46) | NR3C1L3MBTL1HTTPARP1MEN1 | |
| SCHEMBL4512045 | 0.82 | L3MBTL1 (0.55) | NR3C1L3MBTL1HTTPARP1KMT2A | |
| SCHEMBL4518221 | 0.81 | NR3C1 (0.58) | NR3C1 | |
| SCHEMBL4503076 | 0.81 | NR3C1 (0.58) | NR3C1 | |
| SCHEMBL4519006 | 0.79 | HTT (0.43) | NR3C1L3MBTL1HTTPARP1MEN1 | |
| SCHEMBL4518235 | 0.77 | ALDH1A1 (0.44) | NR3C1L3MBTL1ALDH1A1HTTMEN1 | |
| SCHEMBL5322474 | 0.76 | NR3C1 (0.55) | NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2009-04-09 | — | — | US | disclosed |
| EP-1807391-A1 | NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | AstraZeneca AB (SE) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006046916-A1 | NOVEL SULPHONAMIDE DERIVATIVES AS GLUCOCORTICOID RECEPTOR MODULATORS FOR THE TREATMENT OF INFLAMMATORY DISEASES | ASTRAZENECA AB (SE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093485-A1 | Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases | NR3C1, NR3C2, NR5A1 | NR3C1 1/4885L3MBTL1 4844/4885ATM 3925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.